Compare Heron Therapeutics Inc (HRTX) vs Texas Instruments Incorporated (TXN) Price & Performance

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Texas Instruments (TXN) trades at $284.07, showing minimal daily movement (+0.02%). The stock demonstrates strong profitability with 29.11% net margins and 32.18% ROE, though valuation metrics appear elevated with a P/E of 48.55. Recent Q1 2026 earnings beat expectations at $1.68 EPS versus $1.36 expected, while technical indicators show bearish momentum despite crossing above the 20-day moving average according to Zacks (June 3, 2026).

The company faces mixed signals with improving operational cash flow ($7.15B in 2025) and AI-driven demand growth offset by declining profit margins and rising debt levels. Analyst consensus remains positive with a $317.20 price target, though technical weakness and competitive pressures in semiconductors present near-term headwinds for shareholders.